Columbia Laboratories, Inc. has renewed its license and supply agreement with Merck Serono for Crinone (progesterone gel) for an additional five years. Under the agreement and the renewal, Merck Serono has worldwide marketing rights, outside of the U.S. Crinone is currently approved in 63 countries. “We are pleased to continue our longstanding relationship with Merck Serono for Crinone,” said Frank C. Condella, Jr., Columbia’s president and chief executive officer. “We expect sales volumes wi...